(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer

Abdom Imaging. 2015 Aug;40(6):1769-71. doi: 10.1007/s00261-014-0301-z.

Abstract

Current imaging procedures for prostate cancer including positron emission tomography (PET) exhibit considerable limitations and are not always able to meet the diagnostic needs. Recently, a (68)Gallium-labeled ligand of the prostate-specific membrane antigen ((68)Ga-PSMA) has been introduced in PET-imaging of prostate cancer with first promising results. Due to relatively exclusive expression of PSMA in prostatic tissue as well as increased expression in prostate cancer, 68 Ga-PSMA was reported to exhibit a favorable lesion to background ratio. Together with the novel development of combined PET/MRI, the combination of excellent morphological detail, multiparametric functional information, and molecular PET data might lead to a significant improvement in detection of prostate cancer. We present an exemplarily case of primary staging using multiparametric (68)Ga-PSMA PET/MR by combining molecular and structural information.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antigens, Surface
  • Edetic Acid / analogs & derivatives*
  • Gallium Radioisotopes*
  • Glutamate Carboxypeptidase II
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Multimodal Imaging
  • Neoplasm Staging / methods
  • Oligopeptides*
  • Positron-Emission Tomography
  • Preoperative Care
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / surgery

Substances

  • Antigens, Surface
  • Gallium Radioisotopes
  • Oligopeptides
  • gallium 68 PSMA-11
  • Edetic Acid
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II